Table 4.
Adverse events after intervention.
| Characteristics | Vitamin C Group (n = 70) |
Placebo Group (n = 71) |
|---|---|---|
| Withdrawal from trial for adverse events, n (%) | 0 (0) | 0 (0) |
| Patients with ≥ 1 adverse events 2 hours after trial, n (%) | 16 (22.9) | 11 (15.4) |
| Patients with ≥ 1 adverse events 1 day after trial, n (%) | 4 (5.7) | 4 (5.6) |
| Total adverse events, n | 24 | 17 |
| Patients who experienced specific adverse events 2 hours after intervention, n (%) | ||
| itching sense/pain at injection site | 9 (12.9) | 8 (11.3) |
| dry mouth | 7 (10) | 2 (2.8) |
| others* | 4 (5.7) | 3 (4.2) |
| Patients who experienced specific adverse events 1 day after intervention, n (%) | ||
| itching sense/pain at injection site | 1 (1.4) | 3 (4.2) |
| dry mouth | 1 (1.4) | 0 (0) |
| diarrhea | 1 (1.4) | 0 (0) |
| common cold symptoms | 1 (1.4) | 1 (1.4) |
*Other adverse events included chest discomfort, palpitations, sweating, and abdominal discomfort in the vitamin C group and dizziness, fatigue, and myalgias in the placebo group. These adverse events occurred in one case each.